Clinical Trial Update: The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer [Phase 2, Phase 3]

View source ↗

Summary

This entry reports the completion of the MAX Study, a Phase 2/3 trial evaluating mitomycin C, bevacizumab (Avastin), and capecitabine (Xeloda) in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Mitomycin-C (mitomycin C)
• Xeloda (capecitabine)

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Metastatic Colorectal Cancer | Phase 2, Phase 3 | Status: COMPLETED